GSK has a chance to prove itself after next week's Haleon split. Will M&A follow?

Come Monday, GSK and consumer health unit Haleon will officially part ways, leaving the Big Pharma's biopharma and vaccines divisions to stand on their own. This will give the drugmaker—and its CEO Emma Walmsley—a chance to prove themselves after a long period of questioning from some market watchers and investors.